Skip to Main Content

Bristol Myers Squibb said Tuesday that an oral drug designed to treat psoriasis differently from currently approved medicines demonstrated superiority to placebo and a competing drug from Amgen — achieving the goals of a large Phase 3 clinical trial.

The safety profile of the Bristol drug called deucravacitinib, was “consistent” with previously conducted studies, the company added.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!